Sangamo Therapeutics Appoints Gary H. Loeb as Executive Vice President and General Counsel
July 31 2019 - 4:15PM
Business Wire
Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine
company, announced today the appointment of Gary H. Loeb as
Executive Vice President and General Counsel, effective
immediately. Mr. Loeb will oversee all legal matters for Sangamo
and will report to the Chief Executive Officer.
“Gary brings dynamic experience in pharmaceutical compliance,
legal operations, and executive leadership,” said Sandy Macrae,
Sangamo's Chief Executive Officer. “We are pleased Gary is joining
Sangamo and look forward to his contributions as Sangamo continues
to grow as a clinical stage development company, and eventually
into commercialization.”
Mr. Loeb has over 20 years of experience in biotechnology and
pharmaceutical law, compliance, intellectual property, litigation,
human resources, regulatory, and facilities. Before joining
Sangamo, he served as General Counsel, Corporate Secretary, and
Chief Compliance Officer at Achaogen, an anti-infectives company.
At Achaogen, Mr. Loeb was a member of the Executive Team and the
first full-time in-house attorney, where he built the legal and
compliance teams. Before Achaogen, Mr. Loeb worked in roles of
increasing responsibility at Counsyl, a genetic screening company,
Amyris, Inc., and Genentech.
Mr. Loeb received his B.S. and B.A. degrees from Stanford
University and his J.D. from Columbia Law School.
About Sangamo Therapeutics
Sangamo Therapeutics is committed to translating ground-breaking
science into genomic medicines with the potential to transform
patients’ lives using gene therapy, ex vivo gene-edited cell
therapy, and in vivo genome editing and gene regulation. For more
information about Sangamo, visit www.sangamo.com
Forward-Looking Statements
This press release contains forward-looking statements regarding
Sangamo's current expectations. These forward-looking statements
include, without limitation, references to Sangamo's anticipated
growth as a clinical stage development company and into
commercialization. These statements are not guarantees of future
performance and are subject to certain risks, uncertainties and
assumptions that are difficult to predict. Factors that could cause
actual results to differ include, but are not limited to, risks and
uncertainties related to: the costly and inherently uncertain
research and development process; the completion of clinical trials
of Sangamo’s product candidates; Sangamo’s limited experience in
conducting later stage clinical trials and the potential inability
of Sangamo and its partners to advance Sangamo’s product candidates
into registrational studies; Sangamo's reliance on third-parties to
meet their clinical and manufacturing obligations; Sangamo’s
ability to maintain strategic partnerships; Sangamo’s ability to
manage its growth; Sangamo’s current lack of infrastructure or
capability to manufacture, market and sell therapeutic products on
a commercial scale; and the potential for technological
developments by Sangamo's competitors that will obviate Sangamo's
gene therapy technology. Further, there can be no assurance that
the necessary regulatory approvals will be obtained for Sangamo’s
product candidates or that Sangamo and its partners will be able to
develop commercially viable product candidates. Actual results may
differ from those projected in forward-looking statements due to
these and other risks and uncertainties that exist in Sangamo's
operations and business environments. These risks and uncertainties
are described more fully in Sangamo's Quarterly Report on Form 10-Q
for the quarter ended March 31, 2019 as filed with the Securities
and Exchange Commission. Forward-looking statements contained in
this press release are made as of this date, and Sangamo undertakes
no duty to update such information except as required under
applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190731005868/en/
Investor Relations – Global McDavid
Stilwell 510-970-6000, x219 mstilwell@sangamo.com
Media Inquiries – Global Aron
Feingold 510-970-6000, x421 afeingold@sangamo.com
Investor Relations and Media Inquiries –
European Union & United Kingdom Caroline Courme 33 4 97
21 27 27 ccourme@sangamo.com
Sangamo Therapeutics (NASDAQ:SGMO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Sangamo Therapeutics (NASDAQ:SGMO)
Historical Stock Chart
From Sep 2023 to Sep 2024